Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-EB-PSMA-617 in Adenoid Cystic Carcinoma
NCT04801264Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-EB-PSMA-617 in adenoid cystic carcinoma (ACC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Diagnostic value at 1 year. Status: unknown.
02
Drugs
177Lu-EB-PSMA-617
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT04801264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04801264.